A Fast and Furious Liquid Biopsy Assay to Monitor Targeted Therapy Resistance

Chiara Nicolazzo; Paola Gazzaniga

doi:10.1007/978-1-0716-2513-2_8

A Fast and Furious Liquid Biopsy Assay to Monitor Targeted Therapy Resistance

Methods Mol Biol. 2022:2535:93-104. doi: 10.1007/978-1-0716-2513-2_8.

Authors

Chiara Nicolazzo¹, Paola Gazzaniga²

Affiliations

¹ Cancer Liquid Biopsy Unit, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
² Cancer Liquid Biopsy Unit, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy. paola.gazzaniga@uniroma1.it.

PMID: 35867225
DOI: 10.1007/978-1-0716-2513-2_8

Abstract

Liquid biopsies represent a valid alternative to conventional tissue biopsies, offering a real time molecular picture of tumors in a minimally invasive manner. Of the various circulating biomarkers available for liquid biopsy, circulating tumor cells (CTC) and circulating tumor DNA (ctDNA) are the most intensively studied to date. However, CTC and ctDNA represent different tumor components, therefore, complementary information from both sources might be beneficial. This protocol focuses on the description of a sample processing workflow that allowed for concurrent isolation of CTC and ctDNA from the same source sample. This single tube approach enables simultaneous analysis of multiple biomarkers to better monitor cancer drug resistance.

Keywords: Cancer; Circulating tumor DNA; Circulating tumor cells; EasyPGX; Maxwell®; Predictive biomarker; ScreenCell®; Targeted therapy resistance.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers, Tumor / genetics
Circulating Tumor DNA* / genetics
Drug Resistance, Neoplasm / genetics
Humans
Liquid Biopsy / methods
Neoplastic Cells, Circulating* / pathology

Substances

Biomarkers, Tumor
Circulating Tumor DNA